Table 1.
Clinical characteristics of uveal melanoma patients with brain metastases.
| Demographics (n=116) | |
|---|---|
| Age, median (range) | 54 (range: 18-77) |
| Female (%) | 63 (54.3%) |
| Primary Tumor Site (n=104) | |
| Choroid | 99 (95.2%) |
| Iridociliary bodies | 3 (2.9%) |
| Iris | 2 (1.9%) |
| Initial Site of Metastases in Patients Who Develop Brain Metastases (n=116) | |
| Liver | 88 (75.9%) |
| Bone | 21 (18.1%) |
| Lungs | 20 (17.2%) |
| Brain | 15 (12.9%) |
| Soft tissue | 15 (12.9%) |
| Lymph node | 8 (6.9%) |
| Adrenals | 4 (3.4%) |
| Other organs involved at time of symptomatic brain metastasis, median (range) | 3 (range: 0-9) |
| Serum Lactate Dehydrogenase at Time of Brain Metastasis (n=86) | |
| Normal | 30 (34.9%) |
| >1 ULN (%) | 22 (25.6%) |
| >2 ULN (%) | 34 (39.5%) |
| Elevated LDH (%) | 56 (65.1%) |
| Treatment (n=114) | |
| Lines of therapy prior to brain metastasis, median (range) | 3 (range: 0-10) |
| Treatment with ICI prior to brain metastasis (%) | 64 (56.1%) |
| Cytogenetics (n=21) | |
| Monosomy 3 or 3p deletion (%) | 15 (71.4%) |
| 8q amplification (%) | 14 (66.67%) |
| Gene expression profile by DecisionDX-UM (n=13) | |
| Class 1A (%) | 1 (7.7%) |
| Class 1B (%) | 2 (15.4%) |
| Class 2 (%0 | 10 (76.9%) |
| Mutations by Targeted Molecular Panels and Immunohistochemistry | |
| BAP1 (n=33) | 20 (60.6%) |
| SF3B1 (n=22) | 10 (31.3%) |
| EIF1AX (n=32) | 1 (4.5%) |
| Mutations by Next Generation Sequencing (n=34) | |
| GNAQ/GNA11 | 24 (70.1%) |
| BAP1 | 5 (14.7%) |
| PRKCE | 4 (11.8%) |
| MET | 4 (11.8%) |
| CDK2 | 3 (8.8%) |
| BCL2 | 3 (8.8%) |
| CDKN2A | 3 (8.8%) |
| BRAF | 2 (5.9%) |
| SF3B1 | 2 (5.9%) |
| EIF1AX | 1 (2.9%) |
Table 1 describes the clinical characteristics of uveal melanoma patients who develop brain metastases at any point during their disease course. LDH, lactate dehydrogenase. ULN, upper limit of normal. ICI, immune checkpoint inhibitor (Anti-PD1, Anti-PD-L1, Anti-CTLA4).